Highlights
- Institutional investors, including Wellington Management Group LLP and FMR LLC, modified their holdings in Perrigo.
- Director Jeffrey B. Kindler sold 17,598 shares, reducing his position by 76.49%.
- The stock opened at $24.80, trading within a 52-week range of $23.14 to $33.46.
Perrigo Company plc (NYSE:PRGO) has seen significant institutional activity, with Mirae Asset Global Investments Co. Ltd. acquiring 5,900 shares valued at approximately $149,000. Other key institutional investors adjusted their holdings, reflecting ongoing engagement within the company’s stock.
Institutional Investment Developments
Wellington Management Group LLP expanded its stake by over 229% in the third quarter, now holding more than 2.6 million shares. FMR LLC significantly increased its position by 66,795%, bringing its total valuation to $48.27 million. Copeland Capital Management and Allspring Global Investments also expanded their stakes, further contributing to institutional participation. Currently, institutions and hedge funds collectively own 95.91% of Perrigo's stock.
Executive Transactions and Insider Activity
Director Jeffrey B. Kindler sold 17,598 shares in December, amounting to approximately $497,495. This transaction reduced his holdings by 76.49%, leaving him with 5,409 shares in the company. The transaction was officially recorded in a legal filing with the Securities & Exchange Commission, which tracks changes in executive stock ownership.
Stock Performance and Market Valuation
Perrigo’s stock opened at $24.80, fluctuating within a 52-week range of $23.14 to $33.46. Recent stock movements align with financial market trends, while valuation indicators continue to reflect its position within the healthcare sector.
Business Operations and Industry Role
Perrigo specializes in over-the-counter health and wellness products across the United States, Europe, and international markets. The company operates under two primary segments: Consumer Self-Care Americas and Consumer Self-Care International. Its diverse product portfolio includes upper respiratory treatments, nutrition solutions, digestive health products, pain and sleep aids, and oral care items.
With a strong institutional presence and ongoing market activity, Perrigo continues to maintain its role within the self-care and consumer healthcare industry.